Key result
Extracellular vesicles show significant potential as a novel, cell-free therapeutic strategy and drug delivery system for myocardial repair, though clinical translation faces standardization challenges.
Why the study?
Current treatments restore blood perfusion after myocardial infarction but do not reverse myocardial cell loss, leaving the lack of pragmatic methods of myocardial restoration as a major clinical challenge.
Extracellular vesicles offer a promising cell-free therapeutic approach and natural nanocarrier system for myocardial repair following ischemic injury.
Does not yet support clinical use of extracellular vesicles for myocardial repair; leaves open their therapeutic role pending standardized trials.
Cardiovascular disease is the leading cause of human death worldwide. Drug thrombolysis, percutaneous coronary intervention, coronary artery bypass grafting and other methods are used to restore blood perfusion for coronary artery stenosis and blockage. The treatments listed prolong lifespan, however, rate of mortality ultimately remains the same. This is due to the irreversible damage sustained by myocardium, in which millions of heart cells are lost during myocardial infarction. The lack of pragmatic methods of myocardial restoration remains the greatest challenge for effective treatment. Exosomes are small extracellular vesicles (EVs) actively secreted by all cell types that act as effective transmitters of biological signals which contribute to both reparative and pathological processes within the heart. Exosomes have become the focus of many researchers as a novel drug delivery system due to the advantages of low toxicity, little immunogenicity and good permeability. In this review, we discuss the progress and challenges of EVs in myocardial repair, and review the recent development of extracellular vesicle-loading systems based on their unique nanostructures and physiological functions, as well as the application of engineering modifications in the diagnosis and treatment of myocardial repair.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) conducted a review in Myocardial injury and cardiovascular disease. Extracellular vesicles (EVs) was evaluated. Extracellular vesicles show significant potential as a novel, cell-free therapeutic strategy and drug delivery system for myocardial repair, though clinical translation faces standardization challenges.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: